Anna Eramo

1.5k total citations
58 papers, 1.2k citations indexed

About

Anna Eramo is a scholar working on Psychiatry and Mental health, Economics and Econometrics and Clinical Psychology. According to data from OpenAlex, Anna Eramo has authored 58 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Psychiatry and Mental health, 12 papers in Economics and Econometrics and 11 papers in Clinical Psychology. Recurrent topics in Anna Eramo's work include Schizophrenia research and treatment (42 papers), Health Systems, Economic Evaluations, Quality of Life (12 papers) and Mental Health and Psychiatry (11 papers). Anna Eramo is often cited by papers focused on Schizophrenia research and treatment (42 papers), Health Systems, Economic Evaluations, Quality of Life (12 papers) and Mental Health and Psychiatry (11 papers). Anna Eramo collaborates with scholars based in United States, Denmark and Italy. Anna Eramo's co-authors include Ross A. Baker, Timothy Peters-Strickland, Steve Offord, Ruth A. Duffy, Robert D. McQuade, Raymond Sanchez, Anna‐Greta Nylander, John M. Kane, P. Hertel and B. Johnson and has published in prestigious journals such as PLoS ONE, International Journal of Molecular Sciences and The British Journal of Psychiatry.

In The Last Decade

Anna Eramo

55 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Eramo United States	20	841	231	225	185	166	58	1.2k
Heike Hunger Germany	13	1.5k 1.8×	245 1.1×	282 1.3×	273 1.5×	152 0.9×	14	1.9k
Claudia Leucht Germany	14	1.2k 1.5×	333 1.4×	410 1.8×	286 1.5×	96 0.6×	20	1.6k
Dan Zimbroff United States	12	890 1.1×	125 0.5×	317 1.4×	266 1.4×	198 1.2×	21	1.3k
Magdolna Tardy Germany	10	1.0k 1.2×	277 1.2×	384 1.7×	205 1.1×	88 0.5×	13	1.4k
Caroline Corves Germany	6	1.7k 2.0×	369 1.6×	360 1.6×	311 1.7×	221 1.3×	11	2.2k
P. Tran United States	10	1.2k 1.5×	266 1.2×	292 1.3×	453 2.4×	212 1.3×	22	1.9k
Philipp Rothe Germany	10	1.1k 1.3×	193 0.8×	234 1.0×	242 1.3×	119 0.7×	17	1.4k
Mary Anne Dellva United States	16	831 1.0×	171 0.7×	185 0.8×	236 1.3×	74 0.4×	44	1.3k
Michael D. Jibson United States	17	944 1.1×	154 0.7×	280 1.2×	169 0.9×	160 1.0×	57	1.5k
P.V. Tran United States	7	938 1.1×	230 1.0×	174 0.8×	258 1.4×	121 0.7×	15	1.2k

Countries citing papers authored by Anna Eramo

Since Specialization

Citations

This map shows the geographic impact of Anna Eramo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Eramo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Eramo more than expected).

Fields of papers citing papers by Anna Eramo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Eramo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Eramo. The network helps show where Anna Eramo may publish in the future.

Co-authorship network of co-authors of Anna Eramo

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Eramo. A scholar is included among the top collaborators of Anna Eramo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Eramo. Anna Eramo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wong, Dean F., Ganesh B. Chand, Anna Eramo, et al.. (2024). PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement. Neuropsychopharmacology. 50(2). 372–377.

Barone, Annarita, Mariateresa Ciccarelli, Elisabetta Filomena Buonaguro, et al.. (2023). A Postsynaptic Density Immediate Early Gene-Based Connectome Analysis of Acute NMDAR Blockade and Reversal Effect of Antipsychotic Administration. International Journal of Molecular Sciences. 24(5). 4372–4372. 4 indexed citations

McCue, Maggie, James R. King, Francesca Cormack, et al.. (2022). Mobile App to Enhance Patient Activation and Patient-Provider Communication in Major Depressive Disorder Management: Collaborative, Randomized Controlled Pilot Study. JMIR Formative Research. 6(10). e34923–e34923. 10 indexed citations

Opler, Mark, et al.. (2019). <p>Patient attitudes toward and goals for MDD treatment: a survey study</p>. Patient Preference and Adherence. Volume 13. 959–967. 16 indexed citations

Salzman, Phyllis, et al.. (2017). Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole. Neuropsychiatric Disease and Treatment. Volume 13. 1125–1129. 11 indexed citations

Maletic, Vladimir, et al.. (2017). The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review. Frontiers in Psychiatry. 8. 42–42. 118 indexed citations

Buonaguro, Elisabetta Filomena, Felice Iasevoli, Federica Marmo, et al.. (2017). Re-arrangements of gene transcripts at glutamatergic synapses after prolonged treatments with antipsychotics: A putative link with synaptic remodeling. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 76. 29–41. 22 indexed citations

Potkin, Steven G., Jean‐Yves Loze, Carlos Forray, et al.. (2017). Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study. PLoS ONE. 12(8). e0183475–e0183475. 6 indexed citations

Peters-Strickland, Timothy, Anna‐Greta Nylander, Ross A. Baker, et al.. (2017). Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. The International Journal of Neuropsychopharmacology. 20(4). 295–304. 28 indexed citations

10.

Wilson, Michele, Steve Offord, Christopher Blanchette, et al.. (2016). Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs in Context. 5. 1–10. 4 indexed citations

11.

Sapin, Christophe, Ann Hartry, Siddhesh Kamat, et al.. (2016). Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis. Drugs in Context. 5. 1–8. 8 indexed citations

12.

Peters-Strickland, Timothy, Cathy Zhao, Pamela Perry, et al.. (2016). Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics. CNS Spectrums. 21(6). 460–465. 7 indexed citations

13.

Kane, John M., Raymond Sanchez, Ross A. Baker, et al.. (2015). Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies. Clinical Schizophrenia & Related Psychoses. 9(2). 79–87. 15 indexed citations

14.

Peters-Strickland, Timothy, Ross A. Baker, Robert D. McQuade, et al.. (2015). Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study. Schizophrenia. 1(1). 15039–15039. 12 indexed citations

15.

Kane, John M., Cathy Zhao, B. Johnson, et al.. (2014). Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. Journal of Medical Economics. 18(2). 145–154. 41 indexed citations

16.

Citrome, Leslie, Siddhesh Kamat, Christophe Sapin, et al.. (2014). Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. Journal of Medical Economics. 17(8). 567–576. 20 indexed citations

17.

Fleischhacker, W. Wolfgang, Ross A. Baker, Anna Eramo, et al.. (2014). Effects of aripiprazole once-monthly on domains of personal and social performance: Results from 2 multicenter, randomized, double-blind studies. Schizophrenia Research. 159(2-3). 415–420. 21 indexed citations

18.

Fleischhacker, W. Wolfgang, Pamela Perry, Raymond Sanchez, et al.. (2013). Functional Outcomes with Aripiprazole Once-Monthly in Two Double-Blind, Placebo- and Active-Controlled Studies (Aspire US 246 and Aspire EU 247) for the Treatment of Schizophrenia. Value in Health. 16(7). A550–A550. 1 indexed citations

19.

Kamat, Siddhesh, Blanca Gutiérrez, Anna Eramo, et al.. (2013). Initial assessment of real-world usage of extended-release injectable paliperidone palmitate among medicaid insured schizophrenia patients. Value in Health. 16(3). A61–A61. 1 indexed citations

20.

Gardoni, Fabrizio, Elisa Zianni, Anna Eramo, Pier Luigi Canonico, & Mónica Di Luca. (2011). Effect of rasagiline on the molecular composition of the excitatory postsynaptic density. European Journal of Pharmacology. 670(2-3). 458–463. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact